Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Immuneering ( (IMRX) ).
On January 7, 2026, Immuneering announced updated interim results from its ongoing Phase 2a trial of atebimetinib, a once-daily oral MEK inhibitor, combined with modified Gemcitabine/nab-Paclitaxel in first-line pancreatic cancer patients, showing a 64% overall survival rate at 12 months as of the December 15, 2025 cutoff in a 34-patient intent-to-treat cohort at the 320 mg dose, compared with a reported 35% 12‑month overall survival for standard of care, with median overall survival not yet reached and median progression-free survival of 8.5 months. The regimen was generally well tolerated, with no Grade 5 treatment-emergent adverse events and no new safety signals, and Immuneering signaled a rapid development path by planning additional survival and circulating tumor DNA data readouts in 2026, as well as initiating a pivotal Phase 3 trial in first-line pancreatic cancer and a combination trial with Libtayo in non-small cell lung cancer, underscoring its bid to strengthen its position in oncology and potentially enhance treatment options for patients and clinicians.
The most recent analyst rating on (IMRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immuneering stock, see the IMRX Stock Forecast page.
Spark’s Take on IMRX Stock
According to Spark, TipRanks’ AI Analyst, IMRX is a Neutral.
Score is held back primarily by weak financial performance (minimal revenue, persistent losses, and ongoing cash burn). Offsetting this is a strong earnings-call backdrop with encouraging clinical data and an extended cash runway, while technicals are neutral-to-mixed and valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on IMRX stock, click here.
More about Immuneering
Immuneering Corporation operates in the biopharmaceutical industry, developing small-molecule therapies targeting key cancer pathways, with a focus on oral inhibitors such as its MEK inhibitor atebimetinib for hard-to-treat solid tumors including pancreatic cancer and non-small cell lung cancer.
Average Trading Volume: 1,275,679
Technical Sentiment Signal: Buy
Current Market Cap: $426.8M
Find detailed analytics on IMRX stock on TipRanks’ Stock Analysis page.